Myeloma Paper of the Day, June 12th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Pre-clinical study finds acquired resistance to venetoclax characterized by reduced mitochondrial priming & changes in BCL-2 family conferring broad resistance to standard-of-care anti-myeloma drugs.”
Source: Robert Orlowski/X
Authors: Shuhui Deng, Sanika Derebail, Vera Joy Weiler, Jessica Fong Ng, Elena Maroto-Martin, Madhumouli Chatterjee, Giulia Giorgetti, Chandraditya Chakraborty, Poonam Kalhotra, Ting Du, Yao Yao, Rao Prabhala, Masood A Shammas, Annamaria Gulla, Anil Aktas Samur, Mehmet Samur, Lugui Qiu, Kenneth Anderson, Mariateresa Fulciniti, and Nikhil Munshi.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
